Sixteen months from a clinical hold to a pivotal design with a fixed success rule
Rocket’s pivotal Danon trial now counts only patients treated at a lower dose than the one in use when a patient died in 2025.
At least 7 of those 12 must hit two endpoints at once.
At an October 6 investor webinar, Rocket Pharmaceuticals set out the design of the pivotal Phase 2 trial of RP-A501, its AAV9 Danon disease gene therapy, which it calls FDA-aligned. Success requires at least 7 of 12 males to show both LAMP2 protein expression and a drop of at least 10% in left ventricular mass index at 12 months. The first three patients at the new dose showed no sign of the complement-driven toxicity seen before, a finding Rocket calls preliminary.
What Rocket set out
Rocket says the FDA-aligned pivotal efficacy population is 12 male patients receiving commercial-grade RP-A501 at the recalibrated dose. The first three patients treated under the modified protocol count toward it.
Trial success requires at least seven patients to meet both response criteria at 12 months. The criteria are myocardial LAMP2 protein expression of at least Grade 1, and a drop in left ventricular mass index of at least 10% from baseline. Both have to hold in the same patient.
Six misses out of twelve, on either measure, and the trial fails.
The program, in short
- Product: an AAV9 capsid carrying a functional human LAMP2B transgene (AAV9.LAMP2B), given as a single intravenous infusion.
- Disease: Danon disease, an X-linked disorder caused by LAMP2 mutations; the only definitive treatment option is cardiac transplantation.
- Endpoints: co-primary endpoints intended to support a potential accelerated approval pathway.
- Designations: FDA RMAT, Fast Track, Rare Pediatric Disease and Orphan Drug in the U.S., plus ATMP and PRIME in the EU.
- Timing: pivotal dosing complete by mid-2027, topline results anticipated mid-2028.
Why the dose is lower
In May 2025, Rocket reported that a patient in the Phase 2 trial had an unexpected serious adverse event involving capillary leak syndrome. The FDA placed the trial on clinical hold on May 23, 2025.
Rocket said its root cause analysis focused on a novel immune suppression agent recently added to the pre-treatment regimen. The patient later died after an acute systemic infection. The hold is the reason the trial looks the way it does today.
The FDA lifted the hold in August 2025. The FDA authorized the study to resume at 3.8 x 10^13 GC/kg, down from 6.7 x 10^13 GC/kg, first in three patients dosed at least four weeks apart. The new dose is about 43% lower than the original one.
Rocket’s October release links the new dose to the original-dose safety findings, including thrombotic microangiopathy and a fatal serious adverse reaction. Those findings also informed the revised immunomodulation and enhanced safety monitoring. So the pivotal count rests on a dose and regimen with three treated patients behind them so far.
What the data shows, and what it does not
The first three patients at the recalibrated dose completed the initial observation period with no clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome. Rocket calls this preliminary, with follow-up ongoing.
The webinar slides add that one patient had elevated GGT, which resolved, and that patient was discharged after 12 days. Three patients is an early safety signal, not a safety database.
In Phase 1, all six patients in the principal analysis showed LAMP2 expression and at least a 10% drop in left ventricular mass index at about 12 months. At three to seven years, the index was below baseline in five of six and down at least 10% in four.
Those patients were treated at higher doses than the pivotal cohort, 6.7 x 10^13 or 1.1 x 10^14 GC/kg. So the durability data supports the mechanism, not the new dose. Whether 3.8 x 10^13 GC/kg clears both bars is the question the pivotal trial now has to answer.
The slides note that one Phase 1 patient, with an ejection fraction below 40% at entry, needed a heart transplant five months after treatment and was not evaluable. Another had a transplant 4.8 years after infusion, after the data cut.
What this means for a CGT program
Sourced fact: in August 2025 Rocket described a 12-patient pivotal trial that had already treated six patients at the original dose. The October 2026 efficacy population is 12 patients at the recalibrated dose. GTC analysis: as described, the original-dose patients are outside the pivotal count, so on timeline the program needs 12 lower-dose patients rather than 6 more.
GTC analysis: on regulatory design, a fixed responder threshold on two biomarkers at once is a clear, pre-stated test. It also leaves little room: if more than five of twelve miss either criterion, the trial fails as designed.
For a sponsor planning a biomarker-based accelerated approval route, this is a public example of a small, 12-patient pivotal design. Its core is a responder threshold on two co-primary biomarkers, stated well ahead of the readout. The FDA alignment is Rocket’s own description of it.
If you have designed a biomarker-based pivotal endpoint or worked through a clinical hold on an AAV program, GTC's Expert Network matches regulatory experts like you to paid consulting work: join free.
GTC analysis: on CMC, the efficacy population is defined by commercial-grade product. Read at face value, that should narrow the bridging needed between the pivotal data and a marketed product.
Sourced fact: on October 6 Rocket also announced a credit facility of up to $150 million from Hercules Capital. It said its cash, with the first $35 million, should fund planned operations into the third quarter of 2028.
GTC analysis: on budget, that runway ends close to the mid-2028 topline target. Any slip in dosing pushes the readout toward the edge of the funded period, unless further tranches are drawn.
Frequently asked questions
What did Rocket announce about RP-A501 in October 2026?
At an investor webinar on October 6, 2026, Rocket Pharmaceuticals set out the design of its pivotal Phase 2 trial of RP-A501 in Danon disease. The efficacy population is 12 male patients receiving commercial-grade RP-A501 at a recalibrated dose. Rocket describes the trial as FDA-aligned.
What counts as success in the pivotal trial?
At least 7 of the 12 patients must meet both response criteria at 12 months. The criteria are myocardial LAMP2 protein expression of at least Grade 1, and a drop in left ventricular mass index of at least 10% from baseline. Rocket says these co-primary endpoints are intended to support a potential accelerated approval pathway.
Why was the dose changed?
In May 2025 Rocket reported a serious adverse event involving capillary leak syndrome in a Phase 2 patient, who later died after an acute systemic infection. The FDA placed the trial on clinical hold on May 23, 2025 and lifted it in August 2025. The study was authorized to resume at 3.8 x 10^13 GC/kg, down from 6.7 x 10^13 GC/kg, with a revised immunomodulation regimen that dropped a prophylactic C3 complement inhibitor.
How have the first patients at the lower dose done?
Rocket says the first three patients at the recalibrated dose completed the initial observation period without clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome. It describes these observations as preliminary, with follow-up ongoing. Its webinar slides note an elevated GGT in one patient, which resolved.
When are results expected?
Rocket expects to complete dosing in the pivotal trial by mid-2027 and anticipates topline results in mid-2028. Its webinar slides describe the mid-2028 date as provisional and show a BLA filing targeted for late 2028.
Sources
- Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar - Rocket Pharmaceuticals press release via Business Wire, published on BioSpace, October 7, 2026.
- RP-A501 Danon Disease Program Update (investor webinar presentation) - Rocket Pharmaceuticals, Form 8-K Exhibit 99.2, SEC, October 6, 2026.
- Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital - Rocket Pharmaceuticals, Form 8-K Exhibit 99.1, SEC, October 6, 2026.
- Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease - Rocket Pharmaceuticals, Form 8-K Exhibit 99.1, SEC, August 20, 2025.
- Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease - Rocket Pharmaceuticals, Form 8-K Exhibit 99.1, SEC, May 27, 2025.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients: join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy, for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.